CN102295695A - 重组人促卵泡激素及其制备 - Google Patents
重组人促卵泡激素及其制备 Download PDFInfo
- Publication number
- CN102295695A CN102295695A CN2011102699002A CN201110269900A CN102295695A CN 102295695 A CN102295695 A CN 102295695A CN 2011102699002 A CN2011102699002 A CN 2011102699002A CN 201110269900 A CN201110269900 A CN 201110269900A CN 102295695 A CN102295695 A CN 102295695A
- Authority
- CN
- China
- Prior art keywords
- fsh
- carrier
- cell
- subunit
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 title abstract description 3
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 title abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 12
- 102000002287 alpha Subunit Glycoprotein Hormones Human genes 0.000 claims description 43
- 108010000732 alpha Subunit Glycoprotein Hormones Proteins 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 34
- 108010081485 beta Subunit Follicle Stimulating Hormone Proteins 0.000 claims description 32
- 102000035824 beta Subunit Follicle Stimulating Hormone Human genes 0.000 claims description 32
- 238000005571 anion exchange chromatography Methods 0.000 claims description 24
- 102000002067 Protein Subunits Human genes 0.000 claims description 21
- 108010001267 Protein Subunits Proteins 0.000 claims description 21
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 16
- 108010081934 follitropin beta Proteins 0.000 claims description 16
- 238000004587 chromatography analysis Methods 0.000 claims description 15
- 239000002299 complementary DNA Substances 0.000 claims description 12
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 claims description 10
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 10
- 238000002270 exclusion chromatography Methods 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 10
- 230000006303 immediate early viral mRNA transcription Effects 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 108091008146 restriction endonucleases Proteins 0.000 claims description 10
- 229920002684 Sepharose Polymers 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000001890 transfection Methods 0.000 claims description 8
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 7
- 239000012228 culture supernatant Substances 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 6
- 210000001672 ovary Anatomy 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 239000012506 Sephacryl® Substances 0.000 claims description 5
- 108010006578 follitropin alfa Proteins 0.000 claims description 5
- 229940057854 gonal f Drugs 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 4
- 241000699802 Cricetulus griseus Species 0.000 claims description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 4
- 239000013622 capto Q Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- -1 wherein Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003636 conditioned culture medium Substances 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000013598 vector Substances 0.000 abstract description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 32
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 32
- 229940028334 follicle stimulating hormone Drugs 0.000 description 32
- 239000000047 product Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 230000029087 digestion Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000012679 serum free medium Substances 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 239000003292 glue Substances 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010072454 CTGCAG-specific type II deoxyribonucleases Proteins 0.000 description 1
- 238000013449 Capto Q chromatography Methods 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110269900 CN102295695B (zh) | 2011-09-14 | 2011-09-14 | 重组人促卵泡激素及其制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110269900 CN102295695B (zh) | 2011-09-14 | 2011-09-14 | 重组人促卵泡激素及其制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102295695A true CN102295695A (zh) | 2011-12-28 |
CN102295695B CN102295695B (zh) | 2013-07-31 |
Family
ID=45356392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110269900 Active CN102295695B (zh) | 2011-09-14 | 2011-09-14 | 重组人促卵泡激素及其制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102295695B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102786589A (zh) * | 2012-07-30 | 2012-11-21 | 南昌市万华生化药业有限公司 | 重组人促卵泡成熟素rFSH及其基因工程菌株 |
CN105906704A (zh) * | 2016-05-04 | 2016-08-31 | 长春圣金诺生物制药有限公司 | 一种重组人促卵泡激素的纯化方法 |
CN107460206A (zh) * | 2017-09-11 | 2017-12-12 | 深圳市港科深研生物科技有限公司 | 人fsh的重组表达载体、重组细胞株及重组人fsh的制备方法 |
CN109957580A (zh) * | 2019-05-07 | 2019-07-02 | 西北农林科技大学 | 一种表达人促卵泡生长激素(fsh)的方法 |
CN110305903A (zh) * | 2019-07-31 | 2019-10-08 | 江苏璟泽生物医药有限公司 | 重组人促卵泡激素及其制备方法 |
CN112679601A (zh) * | 2021-01-20 | 2021-04-20 | 长春生物制品研究所有限责任公司 | 一种高比活性重组人促卵泡激素的制备方法 |
WO2022141441A1 (zh) * | 2020-12-31 | 2022-07-07 | 南通大学 | 一种促卵泡激素及其体外自组装方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101250531A (zh) * | 2006-11-27 | 2008-08-27 | 株式会社Lg生命科学 | 一核苷酸序列、包含该序列的表达载体、该载体转化的动物细胞以及利用该细胞生产人fsh的方法 |
CN101851287A (zh) * | 2009-04-02 | 2010-10-06 | 上海天伟生物制药有限公司 | 一种高比活绝经期促性腺素及其制备方法和用途 |
-
2011
- 2011-09-14 CN CN 201110269900 patent/CN102295695B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101250531A (zh) * | 2006-11-27 | 2008-08-27 | 株式会社Lg生命科学 | 一核苷酸序列、包含该序列的表达载体、该载体转化的动物细胞以及利用该细胞生产人fsh的方法 |
CN101851287A (zh) * | 2009-04-02 | 2010-10-06 | 上海天伟生物制药有限公司 | 一种高比活绝经期促性腺素及其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
梁成罡等: "重组人促卵泡激素(rhFSH)肽图分析方法研究", 《中国生化药物杂志》, vol. 31, no. 5, 20 October 2010 (2010-10-20), pages 333 - 335 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102786589A (zh) * | 2012-07-30 | 2012-11-21 | 南昌市万华生化药业有限公司 | 重组人促卵泡成熟素rFSH及其基因工程菌株 |
CN105906704A (zh) * | 2016-05-04 | 2016-08-31 | 长春圣金诺生物制药有限公司 | 一种重组人促卵泡激素的纯化方法 |
CN107460206A (zh) * | 2017-09-11 | 2017-12-12 | 深圳市港科深研生物科技有限公司 | 人fsh的重组表达载体、重组细胞株及重组人fsh的制备方法 |
CN107460206B (zh) * | 2017-09-11 | 2020-05-01 | 深圳市深研生物科技有限公司 | 人fsh的重组表达载体、重组细胞株及重组人fsh的制备方法 |
CN109957580A (zh) * | 2019-05-07 | 2019-07-02 | 西北农林科技大学 | 一种表达人促卵泡生长激素(fsh)的方法 |
CN110305903A (zh) * | 2019-07-31 | 2019-10-08 | 江苏璟泽生物医药有限公司 | 重组人促卵泡激素及其制备方法 |
CN110305903B (zh) * | 2019-07-31 | 2021-10-01 | 江苏璟泽生物医药有限公司 | 重组人促卵泡激素及其制备方法 |
WO2022141441A1 (zh) * | 2020-12-31 | 2022-07-07 | 南通大学 | 一种促卵泡激素及其体外自组装方法 |
CN112679601A (zh) * | 2021-01-20 | 2021-04-20 | 长春生物制品研究所有限责任公司 | 一种高比活性重组人促卵泡激素的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102295695B (zh) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102295695B (zh) | 重组人促卵泡激素及其制备 | |
JP3017962B2 (ja) | ヘマトクリット値を上昇させるための医薬組成物の製造方法 | |
CN110845603A (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
CN109851674B (zh) | 一种用于治疗儿童矮小症的重组人血清白蛋白/生长激素融合蛋白的制备纯化方法 | |
JPH0217156B2 (zh) | ||
PT1123313E (pt) | Métodos e composições para a prevenção e tratamento da anemia | |
CN102816244A (zh) | 一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法 | |
CN113121705B (zh) | 用于制备短肽混合物的融合蛋白、目的多肽、短肽混合物的制备方法及应用 | |
CN101240033B (zh) | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 | |
CN113265007B (zh) | 一种治疗代谢疾病的融合蛋白及其制备方法和应用 | |
WO2007107882A2 (en) | Method for purifying granulocyte-colony stimulating factor | |
CN110256575A (zh) | 一种长效重组人生长激素融合蛋白及其工程细胞 | |
CN101134105B (zh) | 用于治疗和/或预防脑梗塞的含有重组人胰激肽原酶的药物组合物 | |
CN101525387B (zh) | 重组长效胰高血糖素样肽类似物及其制备方法 | |
CN112851791B (zh) | 一种新型抗代谢紊乱的fgf类似物及其应用 | |
CN101134953B (zh) | 重组人胰激肽原酶 | |
CN104558198A (zh) | GLP-1类似物和amylin类似物的融合蛋白制备及其用途 | |
CN1962695A (zh) | 类胰高血素肽-1融合蛋白及其制备和用途 | |
CN101875699B (zh) | 人表皮生长因子和金属硫蛋白的融合蛋白及其制备方法和应用 | |
CN101451151A (zh) | 一种利用肿瘤细胞生产生物活性产物的方法 | |
CN105884901A (zh) | 具持续控制血糖含量功能的重组人血清白蛋白/胰高糖素类肽融合蛋白 | |
CN101967468A (zh) | 一种重组人胰激肽原酶 | |
CN100535005C (zh) | 长链人***(lr3igf-1)及其制备和应用方法 | |
CN111424035A (zh) | 基于家蚕丝腺表达具有生物学活性的人***生长因子的方法及其产品和应用 | |
JP2018508465A (ja) | 長時間作用性ctp修飾成長ホルモンポリペプチドを生成する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 130012 No. 72 Tianhe street, hi tech Development Zone, Jilin, Changchun Applicant after: Jinsai Drug Co., Ltd., Changchun Address before: 130012 No. 72 Tianhe street, hi tech Development Zone, Jilin, Changchun Applicant before: Changchun Genscience Pharmaceuticals Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHANGCHUN GENSCI PHARMACEUTICAL CO., LTD. TO: JINSAI MEDICINE CO., LTD., CHANGCHUN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: Changchun Genscience Pharmaceuticals Co., Ltd. Address before: 130012 No. 72 Tianhe street, hi tech Development Zone, Jilin, Changchun Patentee before: Jinsai Drug Co., Ltd., Changchun |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: Jinsai Drug Co., Ltd., Changchun Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: Changchun Genscience Pharmaceuticals Co., Ltd. |